Harnessing CRISPR-Cas to combat COVID-19: from diagnostics to therapeutics
The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global threat with an ever-increasing death toll even after a year on. Hence, the rapid identification of infected individuals with diagnostic tests continues to be crucial in t...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Multidisciplinary Digital Publishing Institute
2021
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/97499/1/ABSTRACT.pdf |
| _version_ | 1825937878927015936 |
|---|---|
| author | Kok, Gan Chan Geik, Yong Ang Yu, Choo Yee Chan, Yean Yean |
| author_facet | Kok, Gan Chan Geik, Yong Ang Yu, Choo Yee Chan, Yean Yean |
| author_sort | Kok, Gan Chan |
| collection | UPM |
| description | The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global threat with an ever-increasing death toll even after a year on. Hence, the rapid identification of infected individuals with diagnostic tests continues to be crucial in the on-going effort to combat the spread of COVID-19. Viral nucleic acid detection via real-time reverse transcription polymerase chain reaction (rRT-PCR) or sequencing is regarded as the gold standard for COVID-19 diagnosis, but these technically intricate molecular tests are limited to centralized laboratories due to the highly specialized instrument and skilled personnel requirements. Based on the current development in the field of diagnostics, the programmable clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins (Cas) system appears to be a promising technology that can be further explored to create rapid, cost-effective, sensitive, and specific diagnostic tools for both laboratory and point-of-care (POC) testing. Other than diagnostics, the potential application of the CRISPR–Cas system as an antiviral agent has also been gaining attention. In this review, we highlight the recent advances in CRISPR–Cas-based nucleic acid detection strategies and the application of CRISPR–Cas as a potential antiviral agent in the context of COVID-19. |
| first_indexed | 2024-03-06T11:06:05Z |
| format | Article |
| id | upm.eprints-97499 |
| institution | Universiti Putra Malaysia |
| language | English |
| last_indexed | 2024-03-06T11:06:05Z |
| publishDate | 2021 |
| publisher | Multidisciplinary Digital Publishing Institute |
| record_format | dspace |
| spelling | upm.eprints-974992022-07-27T06:57:35Z http://psasir.upm.edu.my/id/eprint/97499/ Harnessing CRISPR-Cas to combat COVID-19: from diagnostics to therapeutics Kok, Gan Chan Geik, Yong Ang Yu, Choo Yee Chan, Yean Yean The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global threat with an ever-increasing death toll even after a year on. Hence, the rapid identification of infected individuals with diagnostic tests continues to be crucial in the on-going effort to combat the spread of COVID-19. Viral nucleic acid detection via real-time reverse transcription polymerase chain reaction (rRT-PCR) or sequencing is regarded as the gold standard for COVID-19 diagnosis, but these technically intricate molecular tests are limited to centralized laboratories due to the highly specialized instrument and skilled personnel requirements. Based on the current development in the field of diagnostics, the programmable clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins (Cas) system appears to be a promising technology that can be further explored to create rapid, cost-effective, sensitive, and specific diagnostic tools for both laboratory and point-of-care (POC) testing. Other than diagnostics, the potential application of the CRISPR–Cas system as an antiviral agent has also been gaining attention. In this review, we highlight the recent advances in CRISPR–Cas-based nucleic acid detection strategies and the application of CRISPR–Cas as a potential antiviral agent in the context of COVID-19. Multidisciplinary Digital Publishing Institute 2021 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/97499/1/ABSTRACT.pdf Kok, Gan Chan and Geik, Yong Ang and Yu, Choo Yee and Chan, Yean Yean (2021) Harnessing CRISPR-Cas to combat COVID-19: from diagnostics to therapeutics. Life, 11 (11). art. no. 1210. pp. 1-30. ISSN 2075-1729 https://www.mdpi.com/2075-1729/11/11/1210 10.3390/life11111210 |
| spellingShingle | Kok, Gan Chan Geik, Yong Ang Yu, Choo Yee Chan, Yean Yean Harnessing CRISPR-Cas to combat COVID-19: from diagnostics to therapeutics |
| title | Harnessing CRISPR-Cas to combat COVID-19: from diagnostics to therapeutics |
| title_full | Harnessing CRISPR-Cas to combat COVID-19: from diagnostics to therapeutics |
| title_fullStr | Harnessing CRISPR-Cas to combat COVID-19: from diagnostics to therapeutics |
| title_full_unstemmed | Harnessing CRISPR-Cas to combat COVID-19: from diagnostics to therapeutics |
| title_short | Harnessing CRISPR-Cas to combat COVID-19: from diagnostics to therapeutics |
| title_sort | harnessing crispr cas to combat covid 19 from diagnostics to therapeutics |
| url | http://psasir.upm.edu.my/id/eprint/97499/1/ABSTRACT.pdf |
| work_keys_str_mv | AT kokganchan harnessingcrisprcastocombatcovid19fromdiagnosticstotherapeutics AT geikyongang harnessingcrisprcastocombatcovid19fromdiagnosticstotherapeutics AT yuchooyee harnessingcrisprcastocombatcovid19fromdiagnosticstotherapeutics AT chanyeanyean harnessingcrisprcastocombatcovid19fromdiagnosticstotherapeutics |